Population pharmacokinetic analysis of digoxin in Chinese neonates and infants

Journal of Pharmacological Sciences

Volumn 125, Issue 2, 2014, Pages 142-149

  Gong, Yan ^a   Chen, Yewei ^a   Li, Qin ^a   Li, Zhiping ^a  

^a CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Allometric scaling; Digoxin; Neonate; Nonlinear mixed effects modeling; Pharmacokinetics

Indexed keywords

CREATININE; DIGOXIN; CARDIOTONIC AGENT;

AGE; ARTICLE; BODY WEIGHT; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; GENDER; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL PERIOD; RETROSPECTIVE STUDY; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BLOOD; FEMALE; HEART FAILURE; MALE; PREDICTIVE VALUE;

AGE FACTORS; ASIAN CONTINENTAL ANCESTRY GROUP; BODY WEIGHT; CARDIOTONIC AGENTS; CREATININE; DIGOXIN; FEMALE; HEART FAILURE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84903993515     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.13233FP     Document Type: Article

References (23)

1. Cauffield JS, Gums JG, Grauer K. The serum digoxin concentration: ten questions to ask. Am Fam Physician. 1997;56:495.
2. Wood AJ, Kearns GL, Abdel-Rahman SM, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167. (Pubitemid 37122329)
3. Chen R, Zou S, Wang M, Jiang Y, Xue H, Qian CY, Xia ZL. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Ph. 2012:1-7.
4. Zhou X, Gao Y, Guan Z, Li Z, Li J. Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice. Acta Pharmacol Sin. 2010;31:753-758.
5. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update. J Clin Pharmacol. 1997;37:92-100. (Pubitemid 27131539)
6. Suematsu F, Minemoto M, Yukawa E, Higuchi S. Population analysis for the optimization of digoxin treatment in Japanese paediatric patients. J Clin Pharm Ther. 1999;24:203-208. (Pubitemid 29354037)
7. Suematsu F, Yukawa E, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population-based investigation of relative clearance of digoxin in Japanese neonates and infants by multiple-trough screen analysis. Eur J Clin Pharmacol. 2001;57:19-24. (Pubitemid 32391407)
8. Yukawa E, Suematu F, Yukawa M, Minemoto M, Ohdo S, Higuchi S, et al. Population pharmacokinetics of digoxin in Japanese patients. Clin Pharmacokinet. 2001;40:773-781.
9. Yukawa E, Akiyama K, Suematsu F, Yukawa M, Minemoto M. Population pharmacokinetic investigation of digoxin in Japanese neonates. J Clin Pharm Ther. 2007;32:381-386. (Pubitemid 47063162)
10. Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, et al. Population pharmacokinetic investigation of digoxin in Japanese infants and young children. J Clin Pharmacol. 2011;51:857-863.
11. Petcharattana S. Population pharmacokinetics of digoxin in Thai pediatric patients. J Med Assoc Thai. 2009;92:1324-1335.
12. Martin-Suarez A, Falcao AC, Outeda M, Hernández FJ, González MC, Quero M, et al. Population pharmacokinetics of digoxin in pediatric patients. Ther Drug Monit. 2002;24:742-745. (Pubitemid 35379528)
13. Nagaraja NV, Derendorf H. Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization. Am J Ther. 2001;9:492-498.
14. Desoky ESE, Madabushi R, Amry SEDA, Bhattaram VA, Derendorf H. Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in egyptian pediatric patients with heart failure: does it make sense? Am J Ther. 2005;12:320-327. (Pubitemid 41391810)
15. Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, et al. Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 2013:1-11.
16. Wells TG, Young RA, Kearns GL. Age-related differences in digoxin toxicity and its treatment. Drug Safety. 1992;7:135-151.
17. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122-126. (Pubitemid 27161259)
18. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999;284:1677-1679. (Pubitemid 29291379)
19. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819-829. (Pubitemid 44627767)
20. Bauer LA, Horn JR, Pettit H. Mixed-effect modeling for detection and evaluation of drug interactions: digoxin-quinidine and digoxin-verapamil combinations. Ther Drug Monit. 1996;18: 46-52. (Pubitemid 26033357)
21. Rameis H, Magometschnigg D, Ganzinger U. The diltiazem-digoxin interaction. Clin Pharmacol Ther. 1984;36:183-189. (Pubitemid 14064847)
22. Belz GG, Aust PE, Munkes R. Digoxin plasma concentrations and nifedipine. Lancet. 1981;317:844-845. (Pubitemid 11147454)
23. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010;113:315-324.